KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Inventory (2020 - 2025)

Esperion Therapeutics' Change in Inventory history spans 6 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 123.73% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached $10.6 million, down 63.17%, while the annual FY2025 figure was $10.6 million, 63.17% down from the prior year.
  • Change in Inventory reached -$3.4 million in Q4 2025 per ESPR's latest filing, up from -$5.9 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $15.1 million in Q2 2025 to a low of -$6.4 million in Q2 2022.
  • Average Change in Inventory over 5 years is $4.4 million, with a median of $4.5 million recorded in 2023.
  • Peak YoY movement for Change in Inventory: crashed 274.32% in 2022, then surged 1739.94% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $422000.0 in 2021, then soared by 1240.28% to $5.7 million in 2022, then surged by 150.85% to $14.2 million in 2023, then rose by 1.42% to $14.4 million in 2024, then plummeted by 123.73% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Change in Inventory are -$3.4 million (Q4 2025), -$5.9 million (Q3 2025), and $15.1 million (Q2 2025).